DD-723 Phase III Clinical Trial (Prostate)

DD-723 Phase III Clinical Trial - Confirmatory Study in Subjects with Suspected Prostate Cancer -

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221271

Enrollment

120

Registered

2010-10-19

Start date

2010-10-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subjects with suspected prostate cancer

Interventions

investigational material(s) Generic name etc : DD-723 INN of investigational material : Perflubutane Therapeutic category code : 729 Other diagnostic agents (except extracorporeal diagnostic medicines

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: - Subjects with suspected prostate cancer who are undergoing prostate biopsy. - Subjects whose most recent PSA level is between 20.0 ng/mL and 4.0 ng/mL. - Subjects aged >=20 years old at the time of informed consent.

Exclusion criteria

Exclusion criteria: - Items listed in the package insert (including absolute contraindications, careful administration, and precautions) to ensure safety. - Items related to safety and ethics. - Items related to surgery, procedures, and treatment that are considered likely to influence assessment of the efficacy and safety of DD-723.

Design outcomes

Primary

Measure	Time frame
Detection rate of prostate cancer in the subjects Biopsy results obtained at each participating institution	—

Secondary

Measure	Time frame
1. Detection rate of prostate cancer per biopsy core 2. Assessment of the degree of malignancy 3. Assessment of contrast effect 1, 2. Biopsy results obtained at each participating institution 3. Assessment by investigator	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026